Literature DB >> 12767551

Association of two angiotensinogen gene polymorphisms, M235T and G(-6)A, with chronic heart failure.

Monika Goldbergova1, Lenka Spinarova, Jindrich Spinar, Jirí Toman, Anna Vasku, Jirí Vacha.   

Abstract

The aim of the study was to focus on the relationship between the angiotensinogen (AGT) gene polymorphisms, M235T and promoter G(-6)A, and chronic heart failure in the Czech population. A total of 158 patients with chronic heart failure (functional class NYHA II-IV, ejection fraction <40%, cardiothoracic index >50%) were compared with a control group of 200 subjects of similar age and sex distribution, without any personal history of cardiovascular diseases. The AGT gene polymorphisms were detected by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) methods. No significant differences in distributions of AGT genotypes between patients with chronic heart failure (CHF) and controls were found. The differences in distributions of alleles in AGT M235T (P(a)=0.02) and genotypes in AGT G(-6)A (P(g)=0.017) were found within women groups. Within CHF patients the distribution of AGT G(-6)A genotypes was not consistent with Hardy-Weinberg equilibrium (P=0.0001). We found significant relative risk of CHF in the GGMT genotype, OR=2.63 with 95% CI 1.39-4.95, P(corr)=0.01 (in the male group OR=1.83, 95% CI 0.92-3.66, P(corr)=0.3; in the female group OR=15.5, 95% CI 1.86-129.42, P(corr)=0.008). We provide evidence of increased risk in subjects with the GGMT variant of associated genotype of AGT gene for CHF, especially of fifteen-fold risk of this variant in women.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767551     DOI: 10.1016/s0167-5273(02)00506-5

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  9 in total

1.  RAAS and adrenergic genes in heart failure: Function, predisposition and survival implications.

Authors:  Alberto J Alves; Nir Eynon; José Oliveira; Ehud Goldhammer
Journal:  World J Cardiol       Date:  2010-07-26

Review 2.  Pharmacogenetics of heart failure: evidence, opportunities, and challenges for cardiovascular pharmacogenomics.

Authors:  Matthew T Wheeler; Michael Ho; Joshua W Knowles; Aleks Pavlovic; Euan A Ashley
Journal:  J Cardiovasc Transl Res       Date:  2008-01-29       Impact factor: 4.132

3.  Ten renin-angiotensin system-related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure.

Authors:  Marcin Zakrzewski-Jakubiak; Simon de Denus; Marie-Pierre Dubé; François Bélanger; Michel White; Jacques Turgeon
Journal:  Br J Clin Pharmacol       Date:  2008-02-12       Impact factor: 4.335

Review 4.  Genetic prediction of heart failure incidence, prognosis and beta-blocker response.

Authors:  Fabiana Filigheddu
Journal:  Mol Diagn Ther       Date:  2013-08       Impact factor: 4.074

Review 5.  Determined to Fail--the Role of Genetic Mechanisms in Heart Failure.

Authors:  Elham Kayvanpour; Hugo A Katus; Benjamin Meder
Journal:  Curr Heart Fail Rep       Date:  2015-10

6.  Patients with chronic three-vessel disease in a 15-year follow-up study: genetic and non-genetic predictors of survival.

Authors:  Jan Máchal; Monika Pávková-Goldbergová; Ota Hlinomaz; Ladislav Groch; Anna Vašků
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

7.  The Genetic Variants in the Renin-Angiotensin System and the Risk of Heart Failure in Polish Patients.

Authors:  Iwona Gorący; Anna Gorący; Mariusz Kaczmarczyk; Jakub Rosik; Klaudyna Lewandowska; Andrzej Ciechanowicz
Journal:  Genes (Basel)       Date:  2022-07-15       Impact factor: 4.141

8.  The angiotensinogen gene polymorphism is associated with heart failure among Asians.

Authors:  Wen-long Jiang; Hui-wei He; Zhi-jian Yang
Journal:  Sci Rep       Date:  2014-02-27       Impact factor: 4.379

9.  Angiotensinogen gene polymorphism and ischemic stroke in East Asians: A meta-analysis.

Authors:  Sheng Wang; Rong Zeng; Limin Lei; Jinsong Huang
Journal:  Neural Regen Res       Date:  2013-05-05       Impact factor: 5.135

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.